Loading...
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer
The limited treatment options and therapeutic failure due to acquired resistance for patients with triple-negative breast cancer (TNBC) represent a significant challenge. Inhibitors against poly (ADP-ribose) polymerase (PARP), olaparib and talazoparib, were recently approved for the treatment of met...
Saved in:
| Published in: | Am J Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
e-Century Publishing Corporation
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7061756/ https://ncbi.nlm.nih.gov/pubmed/32195033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|